Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
58.46
-0.54 (-0.92%)
At close: Nov 20, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or 0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$754,676
Profits / Employee
$147,929
Market Cap
377.45B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Veradigm | 2,300 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 105 |
| Silence Therapeutics | 88 |
| Elite Pharmaceuticals | 65 |
| CytoDyn | 14 |
| Revium Rx. | 6 |
Roche Holding AG News
- 4 days ago - Roche Secures First U.S. Approval for New Breast-Cancer Pill - WSJ
- 5 days ago - Genentech announces FDA approval of Wilserdly in combination with everolimus - TheFly
- 5 days ago - FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer - Business Wire
- 5 days ago - FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer - GlobeNewsWire
- 5 days ago - US FDA approves Roche's oral treatment for advanced breast cancer - Reuters
- 5 days ago - Roche receives FDA De Novo authorization for cobas pro i 601 platform - TheFly
- 5 days ago - Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories - PRNewsWire
- 5 days ago - Genentech announces FDA approval of Gazyva for primary membranous nephropathy - TheFly